EyePoint, ImprimisRx expand Dexycu alliance in US
Click Here to Manage Email Alerts
EyePoint Pharmaceuticals and ImprimisRx will expand their U.S. commercial alliance for Dexycu, with ImprimisRx taking control of sales and marketing responsibilities, according to a press release from the companies.
“We are pleased to expand our partnership with EyePoint to continue to bring Dexycu, an innovative FDA-approved injectable steroid product, to patients experiencing inflammation following ocular surgery,” John Saharek, president of ImprimisRx, said in the release.
According to the alliance, ImprimisRx will assume responsibility for the U.S. sales and marketing of Dexycu (dexamethasone intraocular suspension 9%) and absorb the majority of the Dexycu commercial organization.
EyePoint will be responsible for manufacturing and distribution and will recognize net product revenue. In addition, it will pay ImprimisRx a commission based on Dexycu net sales and retain all commercial rights.
The agreement takes effect on Jan. 1, 2022.
Read more about
Click Here to Manage Email Alerts